Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.

Jones TD, Hearn AR, Holgate RGE, Kozub D, Fogg MH, Carr FJ, Baker MP, Lacadena J, Gehlsen KR.

Protein Eng Des Sel. 2016 Nov 1;29(11):531-540. doi: 10.1093/protein/gzw045.

2.

High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.

Ullman C, Mathonet P, Oleksy A, Diamandakis A, Tomei L, Demartis A, Nardi C, Sambucini S, Missineo A, Alt K, Hagemeyer CE, Harris M, Hedt A, Weis R, Gehlsen KR.

PLoS One. 2015 Aug 27;10(8):e0135278. doi: 10.1371/journal.pone.0135278. eCollection 2015.

3.

Pharmacokinetics of engineered human monomeric and dimeric CH2 domains.

Gehlsen K, Gong R, Bramhill D, Wiersma D, Kirkpatrick S, Wang Y, Feng Y, Dimitrov DS.

MAbs. 2012 Jul-Aug;4(4):466-74. doi: 10.4161/mabs.20652. Epub 2012 Jul 1.

4.

Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.

Middleton M, Hauschild A, Thomson D, Anderson R, Burdette-Radoux S, Gehlsen K, Hellstrand K, Naredi P.

Ann Oncol. 2007 Oct;18(10):1691-7. Epub 2007 Aug 20.

PMID:
17709802
5.

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.

Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K.

Blood. 2006 Jul 1;108(1):88-96. Epub 2006 Mar 23.

PMID:
16556892
6.

A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid.

Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, Qiu L, Archer SP, Ponce AE, Sirisoma N, Jiang S, Zhang HZ, Gehlsen KR, Cai SX, Green DR, Tseng B.

Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12095-100. Epub 2005 Aug 15.

7.

The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach.

Jessen KA, English NM, Yu Wang J, Maliartchouk S, Archer SP, Qiu L, Brand R, Kuemmerle J, Zhang HZ, Gehlsen K, Drewe J, Tseng B, Cai SX, Kasibhatla S.

Mol Cancer Ther. 2005 May;4(5):761-71.

8.

Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice.

Hornyak SC, Orentas DM, Karavodin LM, Gehlsen KR.

Vascul Pharmacol. 2005 Mar;42(4):187-93.

PMID:
15820445
9.
10.

Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis.

Agarwala SS, Hellstrand K, Gehlsen K, Naredi P.

Cancer Immunol Immunother. 2004 Sep;53(9):840-1. Epub 2004 May 4. No abstract available.

PMID:
15127238
11.

Histamine dihydrochloride protects against early alcohol-induced liver injury in a rat model.

Hornyak SC, Gehlsen KR, Haaparanta T.

Inflammation. 2003 Oct;27(5):317-27.

PMID:
14635789
12.

Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis.

O'Day SJ, Agarwala SS, Naredi P, Kass CL, Gehlsen KR, Glaspy J.

Melanoma Res. 2003 Jun;13(3):307-11.

PMID:
12777988
13.

The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma.

Beusterien KM, Ackerman SJ, Plante K, Glaspy J, Naredi P, Wood D, Gehlsen K, Agarwala SS.

Support Care Cancer. 2003 May;11(5):304-12. Epub 2003 Jan 28.

PMID:
12720074
14.

Toxicology and toxicokinetics of acute and subchronic administration of histamine dihydrochloride in rats.

Karavodin L, Jensen R, Sarno M, Gehlsen K.

Drug Chem Toxicol. 2003 Feb;26(1):35-49.

PMID:
12643039
15.

A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C.

Lurie Y, Nevens F, Aprosina ZG, Fedorova TA, Kalinin AV, Klimova EA, Ilan Y, Maevskaya MV, Warnes TW, Yuschuk ND, Hellstrand K, Gehlsen KR.

J Viral Hepat. 2002 Sep;9(5):346-53.

PMID:
12225329
16.

Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.

Middleton M, Sarno M, Agarwala SS, Glaspy J, Laurent A, McMasters K, Naredi P, O'Day S, Whitman E, Danson S, Cosford R, Gehlsen K.

J Clin Pharmacol. 2002 Jul;42(7):774-81.

PMID:
12092744
17.

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.

Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P.

J Clin Oncol. 2002 Jan 1;20(1):125-33.

PMID:
11773161
18.

Histamine: a novel approach to cancer immunotherapy.

Hellstrand K, Brune M, Naredi P, Mellqvist UH, Hansson M, Gehlsen KR, Hermodsson S.

Cancer Invest. 2000;18(4):347-55. Review.

PMID:
10808371
19.

Histamine protects T cells and natural killer cells against oxidative stress.

Hansson M, Hermodsson S, Brune M, Mellqvist UH, Naredi P, Betten A, Gehlsen KR, Hellstrand K.

J Interferon Cytokine Res. 1999 Oct;19(10):1135-44.

PMID:
10547153
20.

Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension.

Wade CE, Grady JJ, Kramer GC, Younes RN, Gehlsen K, Holcroft JW.

J Trauma. 1997 May;42(5 Suppl):S61-5. Review.

PMID:
9191698
21.
22.

Heat shock-induced shedding of cell surface integrins in A549 human lung tumor cells in culture.

Majda JA, Gerner EW, Vanlandingham B, Gehlsen KR, Cress AE.

Exp Cell Res. 1994 Jan;210(1):46-51.

PMID:
7505747
23.

Biochemical evidence for a homophilic interaction of the alpha 3 beta 1 integrin.

Sriramarao P, Steffner P, Gehlsen KR.

J Biol Chem. 1993 Oct 15;268(29):22036-41.

24.

High mannose type N-linked oligosaccharides on endothelial cells may influence beta 2 integrin mediated neutrophil adherence in vitro.

Sriramarao P, Berger E, Chambers JD, Arfors KE, Gehlsen KR.

J Cell Biochem. 1993 Mar;51(3):360-8.

PMID:
8501138
25.

Interconnection of integrins alpha 2 and alpha 3 and structure of the basal membrane in colorectal cancer: relation to survival.

Lindmark G, Gerdin B, Påhlman L, Glimelius B, Gehlsen K, Rubin K.

Eur J Surg Oncol. 1993 Feb;19(1):50-60.

PMID:
8436241
27.

Effects of a melanotropic peptide on melanoma cell growth, metastasis, and invasion.

Gehlsen KR, Hadley ME, Levine N, Ray CG, Hendrix MJ.

Pigment Cell Res. 1992 Nov;5(5 Pt 1):219-23.

PMID:
1337602
28.

Identification of a beta 1 integrin on Mycobacterium avium-Mycobacterium intracellulare.

Rao SP, Gehlsen KR, Catanzaro A.

Infect Immun. 1992 Sep;60(9):3652-7.

29.
30.

Role of the alpha v beta 3 integrin in human melanoma cell invasion.

Seftor RE, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, Hendrix MJ.

Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1557-61.

31.

Integrin expression in human melanoma cells with differing invasive and metastatic properties.

Gehlsen KR, Davis GE, Sriramarao P.

Clin Exp Metastasis. 1992 Mar;10(2):111-20.

PMID:
1311225
32.
33.
34.

A neuronal cell line (PC12) expresses two beta 1-class integrins-alpha 1 beta 1 and alpha 3 beta 1-that recognize different neurite outgrowth-promoting domains in laminin.

Tomaselli KJ, Hall DE, Flier LA, Gehlsen KR, Turner DC, Carbonetto S, Reichardt LF.

Neuron. 1990 Nov;5(5):651-62.

PMID:
2223092
35.

Subunit structure of a laminin-binding integrin and localization of its binding site on laminin.

Gehlsen KR, Dickerson K, Argraves WS, Engvall E, Ruoslahti E.

J Biol Chem. 1989 Nov 15;264(32):19034-8.

36.

Endothelial cells use alpha 2 beta 1 integrin as a laminin receptor.

Languino LR, Gehlsen KR, Wayner E, Carter WG, Engvall E, Ruoslahti E.

J Cell Biol. 1989 Nov;109(5):2455-62.

37.

Correction: RuGli cell line not of human origin.

Gehlsen K, Engvall E, Dillner L, Ruoslahti E, Goodman S.

Science. 1989 Jul 28;245(4916):342-3. No abstract available.

PMID:
2526967
38.

The human laminin receptor is a member of the integrin family of cell adhesion receptors.

Gehlsen KR, Dillner L, Engvall E, Ruoslahti E.

Science. 1988 Sep 2;241(4870):1228-9. Erratum in: J Cell Biol 1989 Jun;108(6):following 2546. Science 1989 Jul 28;245(4916):245.

PMID:
2970671
39.

Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides.

Gehlsen KR, Argraves WS, Pierschbacher MD, Ruoslahti E.

J Cell Biol. 1988 Mar;106(3):925-30. Erratum in: J Cell Biol 1989 Jun;108(6):following 2546.

40.
41.

Invasive characteristics of neural crest cells in vitro.

Gehlsen KR, Hendrix MJ.

Pigment Cell Res. 1987;1(1):16-21.

PMID:
3507658
42.
43.

Localization of surface associated antigens before and after tumor cell invasion through a basement membrane.

Hendrix MJ, Gehlsen KR, Brailey JL.

Prog Clin Biol Res. 1986;217B:207-10. No abstract available.

PMID:
3749178
44.

In vitro quantification of melanoma tumor cell invasion.

Hendrix MJ, Gehlsen KR, Wagner HN Jr, Rodney SR, Misiorowski RL, Meyskens FL Jr.

Clin Exp Metastasis. 1985 Oct-Dec;3(4):221-33.

PMID:
4075611
45.

Membrane invasion culture system (MICS).

Gehlsen KR, Wagner HN Jr, Hendrix MJ.

Med Instrum. 1984 Sep-Oct;18(5):268-71.

PMID:
6493100
46.

Scanning and transmission electron microscopic evaluation of human melanoma cells treated with adriamycin and actinomycin D.

Persky B, Peters EM, Gehlsen KR, Sorrentino JM, Meyskens FL Jr, Hendrix MJ.

Scan Electron Microsc. 1983;(Pt 2):983-95.

PMID:
6635583

Supplemental Content

Loading ...
Support Center